Literature DB >> 24439513

Improvements in metabolic abnormalities among overweight schizophrenia and bipolar disorder patients.

A Ventriglio1, A Gentile2, R J Baldessarini3, S Martone2, G Vitrani2, A La Marca2, A Bellomo2.   

Abstract

PURPOSE: As weight-gain and metabolic abnormalities during treatment with psychotropic drugs are of great concern, we evaluated effects of psycho-education and medical monitoring on metabolic changes among severely mentally ill patients.
MATERIALS AND METHODS: During repeated, systematic psycho-education about general health among 66 consecutive patients diagnosed with DSM-IV-TR schizophrenia (n=33) or type-I bipolar disorder (n=33), we evaluated (at intake 1, 2, 3, and 6 months) clinical psychiatric status, treatments and doses, recorded physiological parameters, and assessed attitudes about medication.
RESULTS: At intake, patients with schizophrenia vs bipolar disorder were receiving 3-7 times more psychotropic medication, with 14% higher initial body-mass index (BMI: 29.1 vs 25.6 kg/m²), 12 times more obesity, and significantly higher serum lipid concentrations. During 6-months follow-up, among bipolar disorder patients, polytherapy and serum lipid concentrations declined more than among schizophrenia patients (e.g., total cholesterol+triglycerides, by 3.21 vs 1.75%/month). BMI remained stable. Declining lipid levels were associated with older age, bipolar disorder, being unemployed, higher antipsychotic doses, and lower initial BPRS scores (all P ≤ 0.001).
CONCLUSIONS: Psychotropic treatments were more complex, and metabolic measures more abnormal among bipolar disorder than schizophrenia patients. Intensive psycho-education, clinical monitoring, and encouragement of weight-control for six months were associated with improvements in metabolic measures (but not to BMI), and more realistic attitudes about medication.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antipsychotic drugs; Bipolar disorder; Metabolic syndrome; Obesity; Schizophrenia; Weight-gain

Mesh:

Substances:

Year:  2014        PMID: 24439513     DOI: 10.1016/j.eurpsy.2013.11.005

Source DB:  PubMed          Journal:  Eur Psychiatry        ISSN: 0924-9338            Impact factor:   5.361


  5 in total

Review 1.  Attitudes toward antipsychotic treatment among patients with bipolar disorders and their clinicians: a systematic review.

Authors:  Martha Sajatovic; Faith DiBiasi; Susan N Legacy
Journal:  Neuropsychiatr Dis Treat       Date:  2017-08-30       Impact factor: 2.570

2.  Use of Psychoeducation for Psychotic Disorder Patients Treated With Modern, Long-Acting, Injected Antipsychotics.

Authors:  Antonio Ventriglio; Annamaria Petito; João Maurício Castaldelli-Maia; Julio Torales; Valeria Sannicandro; Eleonora Milano; Salvatore Iuso; Antonello Bellomo
Journal:  Front Psychiatry       Date:  2021-12-15       Impact factor: 4.157

Review 3.  Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management.

Authors:  Antonio Ventriglio; Alessandro Gentile; Eleonora Stella; Antonello Bellomo
Journal:  Front Neurosci       Date:  2015-09-03       Impact factor: 4.677

Review 4.  Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatrists.

Authors:  Simone Pisano; Gennaro Catone; Stefania Veltri; Valentina Lanzara; Marco Pozzi; Emilio Clementi; Raffaella Iuliano; Maria Pia Riccio; Sonia Radice; Massimo Molteni; Annalisa Capuano; Antonella Gritti; Giangennaro Coppola; Annarita Milone; Carmela Bravaccio; Gabriele Masi
Journal:  Ital J Pediatr       Date:  2016-05-21       Impact factor: 2.638

5.  Metabolic Syndrome in Psychotic Disorder Patients Treated With Oral and Long-Acting Injected Antipsychotics.

Authors:  Antonio Ventriglio; Ross J Baldessarini; Giovanna Vitrani; Iris Bonfitto; Angela Chiara Cecere; Angelo Rinaldi; Annamaria Petito; Antonello Bellomo
Journal:  Front Psychiatry       Date:  2019-01-16       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.